Feb 17 () - Disc Medicine said ‌on Tuesday it ‌will pursue a traditional ​U. approval pathway for its rare disease drug ...
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE: MRK) drugs with potential blockbuster sales. Merck's cholesterol treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results